The company said net sales for 2023 were $6,597.0 million, an increase of 7.3% from $6,150.5 million a year earlier, and diluted earnings per share were $5.67, up 13.2% from $5.01 a year earlier.

1. 01

   The company said net sales for 2023 were $6,597.0 million, an increase of 7.3% from $6,150.5 million a year earlier, and diluted earnings per share were $5.67, up 13.2% from $5.01 a year earlier.

2. 02

   AMETEK said consolidated operating income for 2023 was $1,707.5 million, or 25.9% of net sales, up 13.8% from $1,500.7 million (24.4%) a year earlier.

3. 03

   The company said cash provided by operating activities for 2023 was $1,735.3 million, up 51.0% from $1,149.4 million a year earlier, and cited improved working capital management and higher net income as factors behind the increase. Free cash flow was $1,599.1 million.

4. 04

   In 2023, AMETEK spent $2,237.9 million in cash, net of cash acquired, to buy four businesses: Bison, UEI, Amplifier Research and Paragon Medical. It said total debt, net was $3,313.3 million as of year-end 2023, up from $2,385.0 million a year earlier.

Key figures

Fiscal year ended December 31, 2023

Operating income

$1.7B

Net income

$1.3B

EPS

$5.67

Operating cash flow

$1.7B

Analysis scope · Management's discussion (MD&A)We analyzed the Management's Discussion and Analysis (MD&A) section. Other sections of the report, such as the notes to the financial statements and risk factors, were not reviewed.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.